نحوه برخور د با خانم 58 ساله مبتلا به کیست هیداتید

ارائه : دکتر امیرحسین زارع استاد راهنما : جناب آقای دکتر سعیدرضا جمالی 1403/8/26

History

- منبع شرح حال خود بیمار / قابل اعتماد ، همکاری مناسب و مطلع
 - شکایت اصلی : تمدید دارو های آسم
- شرح حال بیماری فعلی : بیمار خانم ۵۸ ساله مورد شناخته شده آسم (از ۱۰ سال پیش) دیابت تیپ ۲ (از ۸ سال پیش) و فشار خون (از ۳ سال پیش) به علت تشدید علائم آسم پس از تمام شدن دارو ها مراجعه کرده است. در صورت مصرف منظم دارو ها شکایتی ندارد.

از درد مکانیکال زانو ها با ارجحیت سمت راست شکایت دارد

بیمار ذکر میکند از ۱۰ سال پیش مبتلا به کیست هیداتید است و جهت پیگری آن سونوگرافی انجام میدهد. در آخرین سونوگرافی کبد، کیسه صفرا و مجاری صفراوی به تاریخ 23 آبان:

تصویر کیست دارای سپتاهای داخلی و محتوای low level echo با ابعاد ۴۹*۶۰ م.م و ۲۱*۲۵ م.م در مجاورت یکدیگر در سگمان ۴ کبد رویت شد. احتمال کیست هیداتید در درجه اول مطرح است.

درد شکم ، تهوع ،استفراغ ، تغییر وزن اخیر ، تغییر اشتها اخیر ، اسهال و یبوست : ندار د



دانشگاه علوم پزشکی و خدمات بهداشتی درمانی تهران بيمارستان ضيائيان گزارش سونوگرافی

نام و نام خانوادگی بیمار: رقیه-قدسی	بخش درخواست کننده: سونوگرافی		
کد پذیرش: ۲۷۹٦۷۲۱ سن بیمار: ۵۷	نام پزشک ارجاع دهنده: مومنی-عباس		
تاریخ پذیرش: ۱۲:۱۱ – ۱٤۰۲/۰۸/۲۱	تاريخ جوابدهى:		
کد برگه: ۱۱۲۰۹۲	کد ملی بیمار: ۰۰٤٩۱۱۲۹۹۱		

شرح حال

درد سونوگرافی کبد، کیسه صفرا و مجاری صفراوی داخل و خارج کبدی

کبد با اندازه و شکل طبیعی رویت شد و ضایعات Solid در آن رویت نشد. تصویر کیست دارای سپتاهای داخلی و محتوای Low Level Echo با ابعاد ۴۹٬۶۶۰ م.م و ۲۵٬۶۱۵ م.م در مجاورت یکدیگر در سگمان ۴ کبد رویت شد. احتمال کیست هیداتید در درجه اول مطرح می باشد. اکوژنیسیته پارانشیم کبد به صورت منتشر افزایش یافته می باشد. (کبد چرب گرید ۲). تطابق با LFT توصيه مي شود.

مجاری صفراوی داخل و خارج کبدی و ورید پورت دیامتر نرمال دارند. کیسه صفرا با ضخامت جداری نرمال رویت شد. سنگ و اسلاج در داخل آن رویت نشد.



نام استاد: دكترمحمد صالح - سيد على # اینستاگرام : radiology.ziaeian

E12382-24-11-13-3





History

• PMH: آسم (از ۱۰ سال پیش) دیابت تیپ ۲ (از ۸ سال پیش) و فشار خون (از ۳ سال پیش)

• DH :

Neb symbicort (Budesonide 320/ Formoterol 9) BD

Tab Airokast (Montelukast 10) daily

Tab Melijent-M (Metformin 500/ Linagliptin 2.5) BD

Tab Losartan (unknown dose) daily

- FH , SH : Neg
- Vitals : BP 137/98 , PR 78 , FBS 153

معاينه: S1, S2, S2 بدون سوفل / شكم نرم و بدون تندرنس / سمع ريه clear / بيمار clear / ill , toxic , icterus
 نبود/ فورس اندام ها 5/5

INTRODUCTION

- Echinococcal disease is caused by infection with the metacestode (larval) stage of the tapeworm Echinococcus.
- prevalent in most areas where livestock is raised in Association with dogs
- The definitive hosts are canines, intermediate hosts sheep,cattle,humans,goats, camels, and horses (*E. granulosus*) mice and other rodents (*E. multilocularis*)
- Four species of *Echinococcus* produce infection in humans;
- *E. granulosus* and *E. multilocularis* : most common, causing cystic echinococcosis (CE) and alveolar echinococcosis (AE), respectively.
- *E. vogeli* and *E. oligarthrus* : cause polycystic echinococcosis , rarely associated with human infection

Clinical manifestations

(E. GRANULOSUS)

Signs and symptoms

- The initial phase of primary infection is always asymptomatic. (Latent periods of more than 50 years reported).
 The clinical presentation of *E. granulosus* infection depends upon the site and size. Small and/or calcified cysts may remain asymptomatic indefinitely. However, symptoms due to mass effect within organs, obstruction of blood or lymphatic flow, or complications such as rupture or secondary bacterial infections can result .
 Hydatid cysts may be found in almost any site of the body(primary inoculation /secondary spread.)
- The liver is affected in approximately two-thirds of patients,
- The lungs in approximately 25 %
- Other organs :brain, muscle, kidneys, bone, heart, pancreas ...

Liver involvement

- Frequently produces **no** symptoms.
- The right lobe is affected in 60 to 85 % of cases.
- Significant symptoms are unusual before the cyst has reached at least **10 cm** in diameter.
- If the cysts become large, **hepatomegaly** with or without associated **right upper quadrant pain**, **nausea**, and **vomiting** can result.
- In approximately one-fourth of the cases, *E. granulosus* cysts rupture into the biliary tree, producing biliary colic, obstructive jaundice, cholangitis, and/or pancreatitis.
- Less commonly, cysts rupture into the peritoneal cavity or other organs, with potential for peritonitis, anaphylaxis, transdiaphragmatically into the pleural space or bronchial tree, causing pulmonary hydatidosis or a bronchial fistula and multiorgan failure.
- Pressure or mass effect on the bile ducts, portal and hepatic veins, or the inferior vena cava can result in cholestasis, portal HTN, venous obstruction, or Budd-Chiari syndrome.
- Secondary bacterial infection of the cysts can result in liver abscesses. (Pyogenic liver abscess)

Lung involvement

- The most common symptoms of pulmonary cystic echinococcosis (CE) :
- Cough (53 to 62 %)
- Chest Pain (49 to 91 %)
- **Dyspnea** (10 to 70 %)
- Hemoptysis (12 to 21 %).
- Less frequent : malaise, nausea and vomiting, and thoracic deformations.
- Cysts can break or develop secondary bacterial infection wich can manifest as a pulmonary abscess with poorly defined margins.
- complication of cyst rupture : pleural cavity involvement can cause pneumothorax, pleural effusion, or empyema.
- 60 % of pulmonary hydatid disease affects the right lung, and 50 to 60 % involve the lower lobes.
- Multiple cysts are common.
- 20 % of patients with lung cysts also have liver cysts

Other organs

- unusual but can lead to significant morbidity and mortality
- Heart : can result in mechanical rupture with widespread dissemination or pericardial tamponade
- CNS : can lead to seizures or signs of raised intracranial pressure; infection of the spinal cord can result in spinal cord compression.
- Kidney: can cause hematuria, flank pain, glomerulonephritis leading to the nephrotic syndrome, and secondary amyloidosis.
- **Bone** : growth of the parasite is a very slow , cysts are usually **asymptomatic** until a **pathologic fracture** develops; the spine, pelvis, and long bones are most frequently affected
- Other : Ocular , Subcutaneous cyst

Cyst rupture : Fever and acute hypersensitivity reactions, including anaphylaxis

Diagnosis

- Generally made by **imaging** in conjunction with **serology**.
- Laboratory findings : Nonspecific leukopenia or thrombocytopenia, mild eosinophilia, and nonspecific liver function abnormalities may be observed but are not diagnostic. Eosinophilia is observed in fewer than 15 % of cases and generally occurs only if there is leakage of antigenic material.
- Imaging :

Ultrasonography : most widely used, easy to perform, inexpensive.

CT or MRI : useful for circumstances in which **greater anatomic detail** is needed to establish the location and number of cysts, the presence or absence of daughter cysts, and presence of ruptured or calcified cysts

Plain radiography : may demonstrate calcification within a cyst but **cannot detect uncalcified** cysts so is not adequate for definitive diagnostic evaluation.

Ultrasonography

- The sensitivity is 90 to 95 %
- The most common appearance : anechoic, smooth, round cyst.
- In the presence of daughter cysts, characteristic internal septation can be seen.
- hydatid sand : hooklets and scolexes from the protoscolices. Hydatid disease is probable in the setting of hydatid sand, inner cyst wall infoldings, and separation of the hydatid membrane from the wall of the cyst observed on ultrasound.
- Ultrasound allows classification of the cyst(s) as active, transitional, or inactive based on biologic activity; such categorizations may influence the choice of treatment.
- Several other classification systems are based upon ultrasound appearance such as WHO's classification

CL CE1 CE2 CE3 CE4 CE5 Cystic lesion Active Active Transitional Inactive Inactive

Ultrasonographic classification of cysts due to cystic echinococcosis

World Health Organization classification of cystic echinococcosis and treatment stratified by cyst stage

WHO stage	Description	Stage	Size	Preferred treatment	Alternate treatment	
CE1	Unilocular unechoic cystic lesion with double	Active	<5 cm	Albendazole alone	PAIR	
	line sign		>5 cm	Albendazole + PAIR	PAIR	
CE2	Multiseptated, "rosette- like" "honeycomb" cyst	Active	Any	Albendazole + either modified catheterization or surgery	Modified catheterization	
CE3a	Cyst with detached membranes (water-lily sign)	Cyst with detached membranes (water-lily	Transitional	<5 cm	Albendazole alone	PAIR
			>5 cm	Albendazole + PAIR	PAIR	
CE3b	Cyst with daughter cysts in solid matrix	Transitional	Any	Albendazole + either modified catheterization or surgery	Modified catheterization	
CE4	Cyst with heterogenous hypoechoic/hyperechoic contents; no daughter cysts	Inactive	Any	Observation	-	
CE5	Solid plus calcified wall	Inactive	Any	Observation	•	

Computed tomography

- Many reports suggest that CT has higher overall sensitivity than ultrasonography (95 to 100 percent) .
- best mode for determining the number, size, and anatomic location of the cysts and is better than ultrasound for detection of extrahepatic cysts.
- CT may also be used for **monitoring** lesions **during therapy** and to detect recurrences.
- CT may be superior to ultrasonography in **assessing for complications** such as infection and intrabiliary rupture.
- ultrasound is better than CT in the investigation of the cyst wall, hydatid sand, daughter cysts, and splitting of the cyst wall
- CT superior for detecting gas and minute calcifications within the cysts, in attenuation measurement, and in anatomic mapping

Magnetic resonance imaging

- MRI is usually not required and, in most instances, is not cost effective. Both CT and MRI are useful in diagnosing echinococcal infection in other sites such as in the brain.
- Advantages over CT : defining changes in the intra- and extrahepatic venous system, delineate the cyst capsule better, at diagnosing complications, particularly for cysts with infection or biliary communication

Serologic tests

- A negative test does not exclude the diagnosis of echinococcosis
- ELISA appears to be the most sensitive and specific of the available assays
- initial screening tests : ELISA and IHA
- Confirmatory tests using specific antigens can then be performed, such as immunoelectrophoresis and immunoblotting.(Detection of antibody to specific echinococcal antigens by immunoblotting has the highest degree of specificity.)
- Additional tests using recombinant or purified species-specific antigens may also be useful diagnosis

Interventional procedures

- biopsy : In the absence of a positive serologic test may be required to confirm the diagnosis . Percutaneous aspiration of liver cyst contents is associated with very low rates of complications. This method is generally reserved for situations when other diagnostic methods are inconclusive because of the potential risk for anaphylaxis and secondary spread of the infection .If aspiration is required, it should be performed under ultrasound or CT guidance; complications can be minimized by concurrent administration of albendazole and praziquantel
- ERCP : may be warranted to evaluate for biliary involvement, particularly in patients with cholestatic jaundice.

Alveolar Echinococcosis (E. Multilocularis)

- Clinical manifestations : usually symptomatic, although the clinical manifestations are frequently nonspecific.
- The most common : malaise, weight loss, and right upper quadrant discomfort due to hepatomegaly. Cholestatic jaundice, cholangitis, portal hypertension, and the Budd-Chiari syndrome can also occur. The clinical presentation may mimic that of hepatocellular carcinoma.
- Extrahepatic primary disease is very rare (1 %). Multiorgan disease was described in 13 % of cases
- Immunodeficiency, such as HIV or transplantation, may accelerate the manifestations of alveolar echinococcosis (AE)
- Nonspecific leukopenia or thrombocytopenia, mild eosinophilia, and nonspecific liver function abnormalities may be detected but are not diagnostic. Hypergammaglobulinemia and elevated serum IgE levels are present in more than 50 % of cases

Alveolar Echinococcosis (E. Multilocularis) Diagnosis

- Generally made by imaging techniques in conjunction with serology.
- Imaging : On ultrasound or CT, the lesions usually have an irregular contour with no welldefined wall, central necrosis, and irregular intralesional and wall calcifications.
- The WHO Informal Work Group on echinococcosis has developed the PNM classification system, which stands for extension of the parasitic mass in the liver (P), the involvement of neighboring organs (N), and metastases (M). The system serves as a benchmark for the evaluation of diagnostic and therapeutic measures.
- Obstruction of the inferior vena cava or of the portal venous system may be evident, which may be more easily appreciated on MRI.
- Lung, brain, and bone lesions may also be detected.

PNM classification of alveolar echinococcosis

P	Hepatic localization of the parasite
PX	Primary tumor cannot be assessed
PO	No detectable tumor in the liver
P1	Peripheral lesions without proximal vascular and/or biliar involvement
P2	Central lesions with proximal vascular and or biliar involvement of 1 lobe*
P3	Central lesions with hilar vascular of biliar involvement of both lobes and/or with involvement of 2 hepatic veins
P4	Any liver lesion with extension along the vessels and the biliary tree [¶]
N	Extrahepatic involvement of neighboring organs (diaphragm, lung, pleura, pericardium, heart, gastric and duodenal wall, adrenal glands, peritoneum, retroperitoneum, parietal wall [muscles, skin, bone], pancreas, regional lymph nodes, liver ligaments, kidney)
NX	Not evaluable
NO	No regional involvement
N1	Regional involvement of contiguous organs or tissues
М	The absence or presence of distant metastasis (lung, distant lymph nodes, spleen, central nervous system, orbital, bone, skin, muscle, kidney, distant peritoneum, and retroperitoneum)
MX	Not completely evaluated
MO	No metastasis [∆]
M1	Metastasis

PNM classification denotes the extension of the parasitic mass in the liver (P), involvement of neighboring organs (N), and metastases (M).

* For classification, the plane projecting between the bed of the gall bladder and the inferior vena cava divides the liver in two lobes.

¶ Vessels mean inferior vena cava, portal vein and arteries.

Δ Chest X-ray and cerebral computed tomography negative.



Alveolar Echinococcosis (E. Multilocularis) Diagnosis

- Serology : The likelihood of a positive serology depends on cyst location and viability. Patients with liver cysts are more likely to be seropositive than patients with lung cysts. Serologic assays are less likely to be positive in the setting of calcified or nonviable cysts. In addition, the sensitivity and specificity of serology is greater for E. multilocularis than for E. granulosus
- biopsy If aspiration is required, it should be performed under ultrasound or CT guidance. Complications can be minimized by concurrent administration of albendazole and praziquantel

Treatment

- Management options for cystic echinococcosis (CE) include surgery, percutaneous management, drug therapy, and observation. In general, clinical approach depends on the World Health Organization (WHO) diagnostic classification
- In general, the approach to treatment of alveolar echinococcosis consists of surgery. Infected tissues should be removed as completely as possible, which requires complete excision of parasitic tissue and may also warrant radical resection of host tissue. In general, at least two years of adjunctive drug therapy is advisable in conjunction with at least 10 years of follow-up monitoring for recurrence.

World Health Organization classification of cystic echinococcosis and treatmen stratified by cyst stage

WHO stage	Description	Stage	Size	Preferred treatment	Alternate treatment	
CE1	Unilocular unechoic cystic lesion with double line sign	nilocular unechoic Active	<5 cm	Albendazole alone	PAIR	
			>5 cm	Albendazole + PAIR	PAIR	
CE2	Multiseptated, "rosette- like" "honeycomb" cyst	Active	Any	Albendazole + either modified catheterization or surgery	Modified catheterization	
CE3a	Cyst with detached membranes (water-lily sign)	Cyst with detached T membranes (water-lily sign)	Transitional	<5 cm	Albendazole alone	PAIR
				>5 cm	Albendazole + PAIR	PAIR
CE3b	Cyst with daughter cysts in solid matrix	Transitional	Any	Albendazole + either modified catheterization or surgery	Modified catheterization	
CE4	Cyst with heterogenous hypoechoic/hyperechoic contents; no daughter cysts	Inactive	Any	Observation		
CE5	Solid plus calcified wall	Inactive	Any	Observation		

Albendazole is dosed 10 to 15 mg/kg per day in two divided doses; the usual dose for adults is 400 mg twice daily. Duration of therapy is discussed in the text.

WHO: World Health Organization; CE: cystic echinocococcis; PAIR: puncture, aspiration, injection, reaspiration.

Data from:

 Junghanss T, da Silva AM, Horton J, et al. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg 2008; 79:301.

Stage-specific treatment approach to alveolar echinococcosis

WHO Classification	Surgery	Interventional treatment	Drug therapy	Suggested	Resource
P1N0M0	x		x	Radical resection (R0) BMZ for 2 years PET/CT controls	Optimal
				Radical resection (R0) BMZ for 3 months	Minimal
P2N0M0	x		x	Radical resection (R0) BMZ for 2 years	Optimal
				Radical resection (R0) BMZ for 3 months	Minimal
P3N0M0			x	BMZ continuously PET/CT/MRI scan initially and in 2 years intervals	Optimal
				BMZ continuously	Minimal
P3N1M0		x	x	BMZ continuously plus PET/CT/MRI scan initially and in 2 years intervals	Optimal
				Surgery, if indicated	Minimal
P4N0M0		x	x	BMZ continuously plus PET/CT/MRI scan initially and in 2 years intervals	Optimal
			Surgery, if indicated	Minimal	
P4N1M1		x	x	BMZ continuously plus PET/CT/MRI scan initially and in 2 years intervals	Optimal
				Surgery, if indicated	Minimal

R0: no residue following resection; BMZ: benzimidazoles; PET: positron emission tomography; CT: computed tomography; MRI: magnetic resonance imaging.

Reproduced from: Brunetti E, Kern K, Vuitton DA, Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Tropica 2009; 114:1. Table used with the permission of Elsevier Inc. All rights reserved.

Primary prevention

cystic echinococcosis :

avoiding close contact with dogs hand washing after handling dogs, and before handling food Restrict home slaughter of sheep and other livestock preventing dogs from consuming infected sheep viscera Elimination of stray dogs Administration of **praziquantel** treatment to infected dogs Vaccination of sheep may also be useful for prevention no available vaccine against the adult echinococcus infection in dogs

Primary Prevention

alveolar echinococcosis

avoidance of contact with foxes and other potentially infected definitive hosts (cats)

Wash hands with soap and warm water after handling dogs, and before handling food Reducing contact between pets and rodent prey intermittent prophylactic treatment of canids with praziguantel (Praziguantel-impregnated bait)

No effective vaccine against *E. multilocularis* has been developed (Even if a vaccine became available, the primary cycle is almost always sylvatic, which makes a vaccination approach to control unlikely to be fully effective)

Secondary Prevention

- For asymptomatic individuals in endemic areas, screening with imaging and serology has been found useful in epidemiologic studies ; outside of endemic areas, the role of screening for asymptomatic individuals is uncertain
- The methods most frequently employed for initial screening tests (using crude antigens such as hydatid fluid or protoscolex extracts) are ELISA and IHA
- Simple, heat-stable, inexpensive tests, such as hydatid antigen dot immunoassays, are often used for field testing and population screening
- Portable ultrasound for screening patients in communities in which *E.granulosus* infection is endemic, sometimes
 with confirmatory serologic testing to maximize the diagnostic yield

Tertiary Prevention

- انتخاب روش مناسب برای درمان (رژیم دارویی و تکنیک جراحی مناسب)
- توجه به عوارض روش های تشخیصی و درمانی تهاجمی (بیوپسی ، PAIR ، ERCP) و انجام آن توسط افراد ماهر

Quaternary Prevention

• Antiparasitic agents should not be used in patients with significant underlying liver disease or bone marrow suppression

